Ascendis Pharma A/S (ASND) EPS Estimated At $-0.90

March 21, 2018 - By Marguerite Chambers

 Ascendis Pharma A/S (ASND) EPS Estimated At $ 0.90

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.90 EPS on March, 28.They anticipate $0.35 EPS change or 63.64 % from last quarter’s $-0.55 EPS. After having $-1.22 EPS previously, Ascendis Pharma A/S’s analysts see -26.23 % EPS growth. The stock increased 1.75% or $1.1 during the last trading session, reaching $64.1. About 240,045 shares traded or 24.00% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since March 21, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma had 21 analyst reports since September 26, 2016 according to SRatingsIntel. On Thursday, January 25 the stock rating was maintained by Bank of America with “Buy”. Wedbush initiated the shares of ASND in report on Monday, September 26 with “Outperform” rating. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Friday, January 5. Wedbush has “Buy” rating and $62.0 target. The firm earned “Outperform” rating on Friday, March 24 by Wedbush. Credit Suisse maintained the shares of ASND in report on Friday, September 22 with “Outperform” rating. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) on Monday, September 11 with “Buy” rating. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) on Thursday, September 28 with “Buy” rating. The stock has “Buy” rating by Bank of America on Friday, November 17. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Tuesday, February 6 by Wedbush. As per Friday, September 22, the company rating was maintained by Wedbush.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.66 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.